(VIANEWS) – The Market ended the session with BENEVOLENTAI (BAI.AS) rising 20.45% to €0.65 on Monday while AEX-Index fell 0.1% to €932.85.
BENEVOLENTAI’s last close was €0.54, 79.77% under its 52-week high of €2.66.
About BENEVOLENTAI
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
Earnings Per Share
As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-0.63.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.01%.
Volume
Today’s last reported volume for BENEVOLENTAI is 41400 which is 266.72% above its average volume of 11289.
Volatility
BENEVOLENTAI’s last week, last month’s, and last quarter’s current intraday variation average was 2.41%, 0.54%, and 3.46%.
BENEVOLENTAI’s highest amplitude of average volatility was 4.54% (last week), 3.42% (last month), and 3.46% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth declined by 64.4%, now sitting on 7.33M for the twelve trailing months.
More news about BENEVOLENTAI (BAI.AS).
